Analysis of Risk Factors for a Low Immune Response to Messenger RNA COVID-19 Vaccine in Kidney Transplant Recipients and Differences Between Second and Third Dose
Authors:
- 24 October 2022
- journal article
- research article
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (10) , 2646-2651
Abstract
No abstract availableKeywords
Funding Information
- Università degli Studi dell'Aquila
This publication has 17 references indexed in Scilit:
- Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravelyAmerican Journal of Transplantation, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- COVID-19 in Solid Organ Transplantation: Disease Severity and Clinical UpdateTransplantation Proceedings, 2021
- Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virusAmerican Journal of Transplantation, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- COVID-19 infection in kidney transplant recipients at the epicenter of pandemicsKidney International, 2020
- COVID-19 and kidney transplantation: Results from the TANGO International Transplant ConsortiumAmerican Journal of Transplantation, 2020
- COVID-19 in solid organ transplant recipients: Initial report from the US epicenterAmerican Journal of Transplantation, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020